WCN26-2257 Crovalimab: Patient preferences and ongoing Phase III COMMUTE trials in atypical haemolytic uraemic syndrome (aHUS)

Read full text Summarise with VIRAT
Authors: Ming‐Hui Zhao, Brittany Gentile, Jennifer Stefani, Muriel Buri, Patty Leon
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

We describe the currently enrolling Phase 3 single-arm COMMUTE-a (NCT04861259) and COMMUTE-p (NCT04958265) trials evaluating crovalimab (crova), a novel C5 inhibitor (C5i), in acute haemolytic uraemic syndrome (aHUS). Crova, with subcutaneous (SC) administration every 4 weeks (Q4W) (or every 2 weeks [Q2W] in patients [pts]

Fields of Study & Subjects

Complement system in diseases Renal Diseases and Glomerulopathies Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
103948–103948
Publication date
25 March 2026
Language
EN